Literature DB >> 15960934

Local recurrence and metastatic disease in a typical N1 carcinoid bronchial tumour.

Miguel Angel Cañizares1, Eva M García-Fontán, José Eduardo Rivo, Ana Gonzalez-Piñeiro.   

Abstract

Typical carcinoid bronchial tumour is a well-known disease that, for years, was considered benign. Currently, it is classified within the group of neuro-endocrine lung tumours. It is a low-grade malignancy tumour with a capability of local and distant recurrence. Complete resection with mediastinal lymphadenectomy is the treatment-of-choice. There are, usually, long-term survivors, even in cases of recurrence or mediastinal node invasion. These patients could benefit from removal of recurrent or metastatic disease. We present, here, a case of a 19-years-old female diagnosed as having N1-bronchial typical carcinoid tumour. She underwent radical surgery, but with mediastinal recurrence and hepatic metastases. A new radical lung resection was performed, and a liver transplant was the therapy-of-choice for the metastatic lesion.

Entities:  

Mesh:

Year:  2005        PMID: 15960934     DOI: 10.1007/bf02712820

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  13 in total

1.  Octreoscan in patients with bronchial carcinoid tumours.

Authors:  Dan Granberg; Anders Sundin; Eva Tiensuu Janson; Kjell Oberg; Britt Skogseid; Jan-Erik Westlin
Journal:  Clin Endocrinol (Oxf)       Date:  2003-12       Impact factor: 3.478

2.  [Bronchial carcinoid tumors: a prospective study].

Authors:  E Pareja; A Arnau; E Artigues; F Peiró; F Hostalet; E Martín; A Cantó
Journal:  Arch Bronconeumol       Date:  1998-02       Impact factor: 4.872

3.  Bronchial carcinoid tumors: surgical management and long-term outcome.

Authors:  Pier Luigi Filosso; Ottavio Rena; Giovanni Donati; Caterina Casadio; Enrico Ruffini; Esther Papalia; Alberto Oliaro; Giuliano Maggi
Journal:  J Thorac Cardiovasc Surg       Date:  2002-02       Impact factor: 5.209

4.  Bronchial carcinoid tumors: long-term outcome after surgery.

Authors:  P Fiala; K Petrásková; S Cernohorský; Z Kinkor; E Krepela; P Zatloukal
Journal:  Neoplasma       Date:  2003       Impact factor: 2.575

5.  Liver metastasis nineteen years after surgery for typical bronchial carcinoid.

Authors:  Y Mokuno; T Katoh; K Yoshida; S Kamiya; H Chigira; M Maeda
Journal:  Hepatogastroenterology       Date:  1999 Sep-Oct

6.  Treatment and prognosis in bronchial carcinoids involving regional lymph nodes.

Authors:  N Martini; M B Zaman; M S Bains; M E Burt; P M McCormack; V W Rusch; R J Ginsberg
Journal:  J Thorac Cardiovasc Surg       Date:  1994-01       Impact factor: 5.209

7.  The feasibility of conservative resection for carcinoid tumours: is pneumonectomy ever necessary for uncomplicated cases?

Authors:  M El Jamal; A G Nicholson; P Goldstraw
Journal:  Eur J Cardiothorac Surg       Date:  2000-09       Impact factor: 4.191

8.  Assessment of outcomes in typical and atypical carcinoids according to latest WHO classification.

Authors:  Maurizio Mezzetti; Federico Raveglia; Tiziana Panigalli; Luigi Giuliani; Fabio Lo Giudice; Stefano Meda; Serena Conforti
Journal:  Ann Thorac Surg       Date:  2003-12       Impact factor: 4.330

Review 9.  Ablative therapies for liver metastases of digestive endocrine tumours.

Authors:  D O'Toole; F Maire; P Ruszniewski
Journal:  Endocr Relat Cancer       Date:  2003-12       Impact factor: 5.678

10.  Clinical-radiological presentation and outcome of surgically treated pulmonary carcinoid tumours: a long-term single institution experience.

Authors:  Liesbet Schrevens; Johan Vansteenkiste; Georges Deneffe; Paul De Leyn; Erik Verbeken; Tine Vandenberghe; Maurits Demedts
Journal:  Lung Cancer       Date:  2004-01       Impact factor: 5.705

View more
  1 in total

1.  Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors.

Authors:  Curtis R Chong; Lori J Wirth; Mizuki Nishino; Aileen B Chen; Lynette M Sholl; Matthew H Kulke; Ciaran J McNamee; Pasi A Jänne; Bruce E Johnson
Journal:  Lung Cancer       Date:  2014-08-27       Impact factor: 5.705

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.